U.S. markets close in 4 hours 30 minutes
  • S&P 500

    4,281.28
    +7.24 (+0.17%)
     
  • Dow 30

    33,942.99
    -37.33 (-0.11%)
     
  • Nasdaq

    12,979.58
    +41.46 (+0.32%)
     
  • Russell 2000

    1,990.69
    +3.37 (+0.17%)
     
  • Crude Oil

    90.39
    +2.28 (+2.59%)
     
  • Gold

    1,776.30
    -0.40 (-0.02%)
     
  • Silver

    19.67
    -0.06 (-0.31%)
     
  • EUR/USD

    1.0138
    -0.0042 (-0.42%)
     
  • 10-Yr Bond

    2.8400
    -0.0530 (-1.83%)
     
  • GBP/USD

    1.2002
    -0.0050 (-0.41%)
     
  • USD/JPY

    135.1120
    +0.0220 (+0.02%)
     
  • BTC-USD

    23,440.61
    -3.14 (-0.01%)
     
  • CMC Crypto 200

    558.88
    +1.15 (+0.21%)
     
  • FTSE 100

    7,531.89
    +16.14 (+0.21%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WALTHAM, Mass., June 02, 2022--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

  • Jefferies Healthcare Conference on June 9, 2022 at 10:00 AM ET in New York, NY

  • JMP Securities Life Sciences Conference on June 15, 2022 at 10:00 AM ET in New York, NY

A live webcast of both events will be available on the "Events and Presentations" page in the "Investors" section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005293/en/

Contacts

Investor Relations:
Maghan Meyers
Argot Partners
Deciphera@argotpartners.com
212-600-1902

Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902